Anti-CD22-Mc-VC-PAB-NMS249 ADC

  • Check with publisher
  • Published date: November 13, 2017
    • Shirley, New York, United States

This ADC product is comprised of an anti-CD22 monoclonal antibody (clone C16) conjugated via a Mc-VC-PAB linker to NMS249. Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.

Anthracyclines (or anthracycline antibiotics) are a class of drugs (CCNS or cell-cycle non-specific) used in cancer chemotherapy derived from Streptomyces bacterium Streptomyces peucetius var. caesius.

Result 0 votes
Bella
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-CD22 (clone hu10F4)-MCC-DM1 ADC

    Anti-CD22 (clone hu10F4)-MCC-DM1 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 (clone hu10F4) monoclonal antibody conjugated via a MCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within...

  • Anti-CD22 (clone G5/44)-AcBut-CalichDMH ADC

    Anti-CD22 (clone G5/44)-AcBut-CalichDMH ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an Anti-CD22 antibody (clone G5/44) conjugated via a AcBut linker to CalichDMH. The CalichDMH is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. With...

  • Anti-CD22-DIBO-doxorubicin ADC

    Anti-CD22-DIBO-doxorubicin ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody conjugated via a DIBO linker to a doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Wi...